Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway
Imidazolopiperazines (IZPs) are a class of compounds under clinical development for malaria, but their mechanism of action is unclear. Here, the authors show that IZPs inhibit the parasite’s secretory pathway, affecting protein trafficking and export.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-15440-4 |